Plasma thrombin-activatable fibrinolysis inhibitor levels are not associated with glucose intolerance and subclinical atherosclerosis in women with previous gestational diabetes

Clinical and Applied Thrombosis/Hemostasis

Volumn 17, Issue 6, 2011, Pages

  Akinci, Baris ^a,b   Celtik, Aygul ^a   Yener, Serkan ^a   Genc, Sinan ^a   Tunali, Sunay ^a   Yuksel, Faize ^a   Ozcan, Mehmet Ali ^a   Secil, Mustafa ^a   Yesil, Sena ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b Izmir Tepecik Training and Research Hospital   (Turkey)

Author keywords

atherosclerosis; fibrinolysis; previous gestational diabetes; TAFI

Indexed keywords

BIOLOGICAL MARKER; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TRIACYLGLYCEROL;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; RISK ASSESSMENT; SUBCLINICAL ATHEROSCLEROSIS;

ADULT; ATHEROSCLEROSIS; CARBOXYPEPTIDASE U; CAROTID INTIMA-MEDIA THICKNESS; CROSS-SECTIONAL STUDIES; DIABETES, GESTATIONAL; FEMALE; FIBRINOLYSIS; GLUCOSE INTOLERANCE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR;

EID: 84857225412     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029610397753     Document Type: Article

References (37)

1. Lijnen HR. Role of fibrinolysis in obesity and thrombosis. Thromb Res. 2009 ; 123 suppl 4: S46 - S49
2. Vaughan DE. PAI-1 and atherothrombosis. J Thromb Haemost. 2005 ; 3 (8). 1879-1883 (Pubitemid 41716575)
3. Trost S, Pratley R, Sobel B. Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes. Curr Diab Rep. 2006 ; 6 (1). 47-54
4. Akinci B, Celtik A, Yener S, Yesil S. Prediction of developing metabolic syndrome after gestational diabetes mellitus. Fertil Steril. 2010 ; 93 (4). 1248-1254
5. Bentley-Lewis R. Late cardiovascular consequences of gestational diabetes mellitus. Semin Reprod Med. 2009 ; 27 (4). 322-329
6. Bo S, Valpreda S, Menato G, et al. Should we consider gestational diabetes a vascular risk factor?. Atherosclerosis. 2007 ; 194 (2). e72 - e79
7. Akinci B, Demir T, Celtik A, et al. Serum osteoprotegerin is associated with carotid intima media thickness in women with previous gestational diabetes. Diabetes Res Clin Pract. 2008 ; 82 (2). 172-178
8. Tarim E, Yigit F, Kilicdag E, et al. Early onset of subclinical atherosclerosis in women with gestational diabetes mellitus. Ultrasound Obstet Gynecol. 2006 ; 27 (2). 177-182 (Pubitemid 43733734)
9. Morimitsu LK, Fusaro AS, Sanchez VH, et al. Fibrinolytic dysfunction after gestation is associated to components of insulin resistance and early type 2 diabetes in latino women with previous gestational diabetes. Diabetes Res Clin Pract. 2007 ; 78 (3). 340-348 (Pubitemid 350030317)
10. Farhan S, Winzer C, Tura A, et al. Fibrinolytic dysfunction in insulin-resistant women with previous gestational diabetes. Eur J Clin Invest. 2006 ; 36 (5). 345-352
11. Bouma BN, Mosnier LO. Thrombin activatable fibrinolysis inhibitor (TAFI)-how does thrombin regulate fibrinolysis?. Ann Med. 2006 ; 38 (6). 378-388 (Pubitemid 44484876)
12. Morser J, Gabazza EC, Myles T, Leung LL. What has been learnt from the thrombin-activatable fibrinolysis inhibitor-deficient mouse?. J Thromb Haemost. 2010 ; 8 (5). 868-876
13. Hori Y, Gabazza EC, Yano Y, et al. Insulin resistance is associated with increased circulating level of thrombin-activatable fibrinolysis inhibitor in type 2 diabetic patients. J Clin Endocrinol Metab. 2002 ; 87 (2). 660-665 (Pubitemid 34158234)
14. Yano Y, Kitagawa N, Gabazza EC, et al. Increased plasma thrombin-activatable fibrinolysis inhibitor levels in normotensive type 2 diabetic patients with microalbuminuria. J Clin Endocrinol Metab. 2003 ; 88 (2). 736-741 (Pubitemid 36207816)
15. Kozian DH, Lorenz M, Marz W, et al. Association between the Thr325Ile polymorphism of the thrombin-activatable fibrinolysis inhibitor and stroke in the Ludwigshafen Risk and Cardiovascular Health Study. Thromb Haemost. 2010 ; 103 (5). 976-983
16. Antovic JP, Yngen M, Ostenson CG, et al. Thrombin activatable fibrinolysis inhibitor and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications. Blood Coagul Fibrinolysis. 2003 ; 14 (6). 551-556 (Pubitemid 37083170)
17. Verkleij CJ, Nieuwdorp M, Gerdes VE, et al. The effects of hyperglycaemia on thrombin-activatable fibrinolysis inhibitor. Thromb Haemost. 2009 ; 102 (3). 460-468
18. Akinci B, Demir T, Saygili S, et al. Gestational diabetes has no additional effect on plasma thrombin-activatable fibrinolysis inhibitor antigen levels beyond pregnancy. Diabetes Res Clin Pract. 2008 ; 81 (1). 93-96
19. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2010 ; 33 (suppl 1). S62 - S69
20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972 ; 18 (6). 499-502
21. Clauss A. Rapid physiological coagulation method in determination of fibrinogen. Acta Haematol. 1957 ; 17 (4). 237-246
22. Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S. Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care. 2009 ; 32 suppl 2: S314 - S321
23. Juhan-Vague I, Renucci JF, Grimaux M, et al. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2000 ; 20 (9). 2156-2161
24. Henry M, Aubert H, Morange PE, et al. Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood. 2001 ; 97 (7). 2053-2058 (Pubitemid 32239086)
25. Harmanci A, Kandemir N, Dagdelen S, et al. Thrombin-activatable fibrinolysis inhibitor activity and global fibrinolytic capacity in Type 1 diabetes: evidence for normal fibrinolytic state. J Diabetes Complications. 2006 ; 20 (1). 40-44 (Pubitemid 43028412)
26. Rigla M, Wagner AM, Borrell M, et al. Postprandial thrombin activatable fibrinolysis inhibitor and markers of endothelial dysfunction in type 2 diabetic patients. Metabolism. 2006 ; 55 (11). 1437-1442 (Pubitemid 44537340)
27. Silveira A, Schatteman K, Goossens F, et al. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb Haemost. 2000 ; 84 (3). 364-368
28. Schroeder V, Chatterjee T, Mehta H, et al. Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography. Thromb Haemost. 2002 ; 88 (6). 1020-1025 (Pubitemid 36018790)
29. Montaner J, Ribo M, Monasterio J, Molina CA, Alvarez-Sabin J. Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke. 2003 ; 34 (4). 1038-1040 (Pubitemid 36402986)
30. Morange PE, Tregouet DA, Frere C, et al. TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study. J Thromb Haemost. 2005 ; 3 (7). 1503-1510 (Pubitemid 41725210)
31. Juhan-Vague I, Morange PE. Very high TAFI antigen levels are associated with a lower risk of hard coronary events: the PRIME Study. J Thromb Haemost. 2003 ; 1 (10). 2243-2244
32. Tregouet DA, Schnabel R, Alessi MC, et al. Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. J Thromb Haemost. 2009 ; 7 (1). 49-57
33. Schroeder V, Wilmer M, Buehler B, Kohler HP. TAFI activity in coronary artery disease: a contribution to the current discussion on TAFI assays. Thromb Haemost. 2006 ; 96 (2). 236-237 (Pubitemid 44219396)
34. Aubert H, Frere C, Aillaud MF, et al. Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome. J Thromb Haemost. 2003 ; 1 (14). 791-797
35. Erdogan M, Karadeniz M, Alper GE, et al. Thrombin-activatable fibrinolysis inhibitor and cardiovascular risk factors in polycystic ovary syndrome. Exp Clin Endocrinol Diabetes. 2008 ; 116 (3). 143-147 (Pubitemid 351518531)
36. Yener S, Comlekci A, Akinci B, et al. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone. Med Princ Pract. 2009 ; 18 (4). 266-271
37. Aso Y, Yamamoto R, Suetsugu M, et al. Comparison of the effects of pioglitazone and voglibose on circulating total and high-molecular-weight adiponectin, and on two fibrinolysis inhibitors, in patients with Type 2 diabetes. Diabet Med. 2007 ; 24 (9). 962-968 (Pubitemid 47301641)